Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

The Estee Lauder Cos Q2 Adj. EPS $1.54 Beats $1.30 Estimate, Sales $4.62B Beat $4.58B Estimate

The Estee Lauder Cos (NYSE:EL) reported quarterly earnings of $1.54 per share which beat the analyst consensus estimate of $1.30 by 18.46 percent. This is a 48.84 percent decrease over earnings of $3.01 per share from
byBenzinga Newsdesk
February 2, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

The Estee Lauder Cos (NYSE:EL) reported quarterly earnings of $1.54 per share which beat the analyst consensus estimate of $1.30 by 18.46 percent. This is a 48.84 percent decrease over earnings of $3.01 per share from the same period last year. The company reported quarterly sales of $4.62 billion which beat the analyst consensus estimate of $4.58 billion by 0.87 percent. This is a 16.61 percent decrease over sales of $5.54 billion the same period last year.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Aptar Awarded U.S. FDA Contract To Study Opportunities For Low Global Warming Potential Propellants For Metered Dose Inhalers; The Contracted Work, Including “Optional Contract Line Items”, Is Valued At Up To ~ $6M

By Benzinga Newsdesk
December 4, 9:30 AM
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, is announcing a contract with the U.S. Food and Drug Administration (FDA) to study the challenges

ATR